IRIS Institutional Research Information System - OPENBS Open Archive UniBS

NODARI, SAVINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.758
AS - Asia 21.660
EU - Europa 19.005
SA - Sud America 4.041
Continente sconosciuto - Info sul continente non disponibili 572
AF - Africa 434
OC - Oceania 90
AN - Antartide 2
Totale 78.562
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.916
CN - Cina 7.655
SG - Singapore 7.346
UA - Ucraina 5.281
IT - Italia 4.168
BR - Brasile 3.434
HK - Hong Kong 2.424
DE - Germania 2.244
FR - Francia 1.567
FI - Finlandia 1.261
IN - India 1.154
GB - Regno Unito 1.139
TR - Turchia 897
VN - Vietnam 861
PL - Polonia 832
IE - Irlanda 808
RU - Federazione Russa 733
CA - Canada 455
SE - Svezia 343
BD - Bangladesh 310
AR - Argentina 226
MX - Messico 213
IQ - Iraq 169
NL - Olanda 156
JP - Giappone 125
ID - Indonesia 110
ES - Italia 109
ZA - Sudafrica 103
PK - Pakistan 95
SA - Arabia Saudita 92
CO - Colombia 91
EC - Ecuador 90
AU - Australia 78
BE - Belgio 68
KE - Kenya 58
UZ - Uzbekistan 58
EG - Egitto 54
VE - Venezuela 51
NG - Nigeria 50
AT - Austria 48
MA - Marocco 46
PY - Paraguay 46
MU - Mauritius 41
MY - Malesia 40
CL - Cile 38
JM - Giamaica 33
CH - Svizzera 32
TW - Taiwan 32
EU - Europa 31
TN - Tunisia 31
NO - Norvegia 29
CR - Costa Rica 28
NP - Nepal 28
AE - Emirati Arabi Uniti 26
PE - Perù 25
PH - Filippine 25
UY - Uruguay 24
KR - Corea 23
CZ - Repubblica Ceca 20
IR - Iran 20
JO - Giordania 20
PT - Portogallo 20
LT - Lituania 19
TT - Trinidad e Tobago 19
BG - Bulgaria 18
IL - Israele 18
HN - Honduras 17
LB - Libano 17
RO - Romania 16
TH - Thailandia 16
KZ - Kazakistan 15
OM - Oman 15
AZ - Azerbaigian 14
ET - Etiopia 14
HU - Ungheria 13
AL - Albania 12
BO - Bolivia 12
DZ - Algeria 12
NI - Nicaragua 12
NZ - Nuova Zelanda 12
BH - Bahrain 11
MD - Moldavia 10
SV - El Salvador 10
BB - Barbados 9
PA - Panama 9
DO - Repubblica Dominicana 8
PR - Porto Rico 8
RS - Serbia 8
SY - Repubblica araba siriana 8
BA - Bosnia-Erzegovina 7
GR - Grecia 6
GT - Guatemala 6
HR - Croazia 6
KG - Kirghizistan 6
KW - Kuwait 6
LK - Sri Lanka 6
LV - Lettonia 6
SK - Slovacchia (Repubblica Slovacca) 6
SC - Seychelles 5
SI - Slovenia 5
Totale 77.947
Salva come PNG Salva come JPEG
Città #
Singapore 3.840
Jacksonville 3.834
Hong Kong 2.405
Ashburn 2.180
Fairfield 1.973
Chandler 1.945
Woodbridge 1.702
Princeton 1.551
Nanjing 1.416
The Dalles 1.409
Beijing 1.406
San Jose 1.329
Ann Arbor 1.244
Houston 1.221
Wilmington 1.218
Cambridge 1.049
New York 956
Columbus 801
Dublin 800
Warsaw 800
Seattle 728
Istanbul 689
Lauterbourg 682
Los Angeles 545
Nanchang 534
Helsinki 468
Milan 457
Buffalo 396
Des Moines 384
Hebei 341
Shenyang 324
São Paulo 313
Ho Chi Minh City 309
Moscow 304
Rome 261
Changsha 258
Tianjin 236
Jiaxing 230
San Diego 189
Kunming 180
Hanoi 171
Dearborn 167
Verona 154
Redondo Beach 151
Jinan 149
Dallas 144
Orem 141
San Francisco 137
Brescia 135
Hangzhou 134
Santa Clara 121
Shanghai 115
Kocaeli 114
Toronto 111
Rio de Janeiro 109
Newton 101
Chicago 99
Mexico City 99
Council Bluffs 98
Boardman 91
Tokyo 90
Munich 81
Brooklyn 78
Guangzhou 76
Zhengzhou 76
Chennai 75
London 75
Naples 75
Frankfurt am Main 73
Belo Horizonte 70
Lancaster 70
Florence 68
Ningbo 61
Vancouver 61
Manchester 60
Atlanta 58
Bologna 56
Lanzhou 55
Baghdad 54
Denver 53
Norwalk 53
Brasília 52
Tashkent 52
Changchun 51
Nairobi 50
Phoenix 50
Montreal 49
Taizhou 49
Abuja 48
Brussels 48
Curitiba 47
Palermo 46
Porto Alegre 46
Boston 45
Pune 43
Nuremberg 42
Salvador 42
Catania 41
Guarulhos 41
Johannesburg 41
Totale 45.749
Salva come PNG Salva come JPEG
Nome #
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 1.368
Un caso di Sindrome di Bland-White-Garland: origine anomala dell’arteria coronaria sinistra dall’arteria polmonare. 729
Inodilatatori: perché e quali. 410
Livelli circolanti del marcatore tumorale CA 125 in pazienti con scompenso cardiaco cronico:relazione con la classe NYHA, i parametri ecocardiografici e variazioni indotte dalla terapia. 374
Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial) 356
Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance 344
Il genotipo DD per il gene dell’enzima di conversione dell’angiotensina identifica i pazienti con insufficienza cardiaca che possono beneficiare di dosi medio elevate di ACE inibitori. 342
Valutazione dell’indice di performance miocardica (MPI) del ventricolo destro con studio eco-doppler in pazienti affetti da insufficienza cardiaca. 332
Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study 264
Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. 260
I polimorfismi Arg16Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca 259
L’ indice di performance miocardica ( MPI ) è un importante indicatore prognostico nei pazienti affetti da insufficienza cardiaca cronica. 239
I polimorfismi Arg16 Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca. 234
Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. 225
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. 222
Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold 220
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 212
Clinical trials update from the World Congress of Cardiology 2006. 198
Fattori di rischio ed “epidemiologia inversa” nei pazienti con insufficienza cardiaca. 195
Valvola aortica quadricuspide asintomatica : un caso clinico. 195
A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. 195
Efficacia di un nuovo diuretico, la muzolimina, in pazienti con insufficienza cardiaca. 194
The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. 193
Determinazione dell’equilibrio simpato-vagale attraverso l’analisi spettrale della variabilità della frequenza cardiaca in pazienti con insufficienza cardiaca di diverso grado di severità. 191
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: Findings from the ASTRONAUT trial 191
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 189
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review 179
Are Beta-1 and alpha2c-adrenergic receptor polymorphisms associated with an increased risk of heart failure in Caucasian subjects: results of a case-control study 174
A rationale for the use of BETA-blockers as standard treatment for heart failure 173
Acute hemodynamic effects of the two dopaminergic agonists ibopamine and dihydroergotamine, a comparison with the parent compound. 171
Serum levels of different tumoral markers in patients with congestive heart failure. 170
Beta- adrenergic receptors polymorphisms and response to CRT 169
Acute heart failure syndromes: assessment and reconstructing the heart. 165
1Beta-2 adrenergic receptors gene polymorphisms influence the effects of carvedilol in the patients with heart failure. 164
A randomized double blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant hypertension. Ca+ Nicardipine. Selected reports from the worldwide literature. 163
The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T 163
Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists 163
Raised homocystein plasma concentration in patients with heart failure: Clinical significance 162
Anemia and heart failure : a cause of progression or only a consequence? 160
Prognostic Value of Serial Clinical, Laboratory and Ecocardiographic Tests in Ambulatory Patients with Chronic Heart Failure 160
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial) 159
Effects of aldosterone blockers on left ventricular function and remodeling in patients with mild-moderate chronic heart failure. 155
Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. 155
Clinical significance of Beta-adrenergic receptor polymorphisms in the patients with chronic heart failure 155
Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients with Chronic Heart Failure 155
Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. 151
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial 151
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial 150
A randomized comparison of the effects of metoprolol and carvedilol on the hemodynamics and functional capacity of patients with heart failure. 149
Acute antianginal efficacy and duration of action of isosorbide 2-mononitrate. 149
Cardiovascular and non cardiovascular comorbidities in patients with chronic heart failure. 149
Nutritional Supplementation with Amino Acids in Ambulatory Patients with Idiophatic Dilatated Cardiomyophaty 148
Significato prognostico indipendente della frequenza cardiaca a riposo alla dimissione come predittore di mortalità in pazienti ricoverati per insufficienza cardiaca acuta. 147
The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. 146
A new dopamine derivative, ibopamine, in the chronic treatment of heart failure: one year follow-up. 145
Asse cuore-rene nell’iperteso cardiopatico. 144
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. 143
Acute and chronic effects of nisoldipine in patients with chronic heart failure. 142
Influence of the angiotensin-converting enzyme genotype on the response to the beta-blocker therapy and the prognosis of the patients with chronic heart failure. 141
Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. 140
Acute hemodynamic and neurohumoral effects of the oral dopamine derivative ibopamine in patients with heart failure. 139
[Chronic heart failure therapy: where we are and where we are going to] 139
A Current treatment in acute and chronic cardio-renal syndrome. 138
Valore prognostico delle variazioni dell'indice di distribuzione dei volumi eritrocitari (RDW) nello scompenso cardiaco cronico. 138
Six-year prognosis of diabetic patients with coronary artery disease. 137
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial) 137
Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure 137
Independent role of resting heart rate at discharge as a predictor of mortality after hospitalisation for acute heart failure. 136
Response to the letter of Hester Den Ruijter and Ruben Coronel regarding the article "the role of n-3 pufas in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy" 136
A new educational program in heart failure drug development: The Brescia international master program 136
Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction 135
Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies 135
Ruolo prognostico della fibrinogemia in pazienti diabetici ricoverati per sindrome coronarica acuta. 134
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion 134
Scompenso cardiaco: meccanismi fisiopatologici e definizioni. 133
Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. 133
Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. 133
Mediterranean diet impact on cardiovascular diseases: A narrative review 133
Weight loss favorably affects the cardiac sympatho-vagal balance of the obese patients: results of power spectral analysis of heart rate variability. 132
Rest and exercise effects of the acute and chronic administration of nisoldipine in patients with heart failure. 131
Different prognostic values of clinical and metabolic parameters in ischaemic diabetic patients with preserved/impaired left ventricular function. 131
[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine] 130
Ibopamine treatment in dopamine dependent heart failure: purpose of a new treatment scheme. 130
Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score 129
Bilancia simpatovagale ed eziologia dell’insufficienza cardiaca: valutazione mediante analisi spettrale della variabilità della frequenza cardiaca. 128
Valutazione emodinamica e neurormonale di tre agenti dopaminergici in pazienti con grave insufficienza cardiaca. 128
Beta-1 adrenoceptor gene polimorphism in heart failure: clinical and prognostic significance in female patients. 128
Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. 128
Redefining biomarkers in heart failure 128
C – Reactive protein and chronic chlamydia pneumoniae infection in patients with acute ischemic syndromes 127
Role of fluid retention in patients hospitalised for acute heart failure. 126
Beta-1 adrenergic receptor gene polimorphism in heart failure: a gender specific clinical and prognostic role? 126
Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms. 126
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions 126
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial 126
The chronic heart failure evolutions: Different fates and routes 125
Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report 125
Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial 125
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries 125
Maximal and submaximal exercise testing in heart failure. 125
Totale 18.689
Salva come PNG Salva come JPEG
Categoria #
all - tutte 399.540
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 399.540
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.875 0 1.082 50 343 85 253 151 371 292 647 523 1.078
2022/20235.509 852 63 48 516 513 1.620 16 565 855 44 194 223
2023/20244.104 333 101 174 234 145 740 121 110 1.207 60 99 780
2024/202510.958 65 57 93 1.249 1.485 762 930 452 1.169 568 2.476 1.652
2025/202620.896 1.917 3.326 1.497 2.917 1.674 1.304 3.230 922 1.276 1.953 592 288
2026/20271.607 1.337 270 0 0 0 0 0 0 0 0 0 0
Totale 78.562